Home/Pipeline/Arynta (lisdexamfetamine dimesylate) Oral Solution, CII

Arynta (lisdexamfetamine dimesylate) Oral Solution, CII

Treatment of ADHD in adults and pediatric patients 6 years and older

ApprovedActive

Key Facts

Indication
Treatment of ADHD in adults and pediatric patients 6 years and older
Phase
Approved
Status
Active
Company

About NextSource Pharma

Azurity Pharmaceuticals is a US-based, private specialty pharma company founded in 2018, with a core mission of serving overlooked patients through customized drug formulations. It has built a commercial-stage portfolio of over 50 products, spanning key therapeutic areas, and utilizes a Next-Gen Commercial Model powered by data, analytics, and AI-driven tools. The company has a global footprint in over 50 countries and recently launched new products like Ferabright and Arynta, demonstrating ongoing pipeline execution and commercial growth.

View full company profile